New Confusion After an Antidepressant Change

October 16, 2026 | The Psychiatric Record | Prescribing

Illustrative workflow example, not a patient case.

An older adult starts an antidepressant. At follow-up, the family describes new difficulty following conversations and an unsteady walk. The mood assessment still matters, but the immediate task has widened: establish what changed, assess the person's medical condition, and consider whether sodium needs checking.

Hyponatremia can enter a psychiatric visit as a cognitive complaint or a change in behavior. Recognizing that possibility connects the medication review with a medical assessment, while keeping other explanations in view.

The U.S. Zoloft prescribing information warns that hyponatremia can occur with SSRIs and SNRIs. It lists impaired concentration, confusion, weakness and unsteadiness among possible manifestations, and identifies older adults, people taking diuretics and those who are volume-depleted as potentially at greater risk.

Severe confusion, markedly reduced alertness, a seizure or collapse warrants emergency assessment. Routine follow-up is insufficient in that situation.

The label directs clinicians to discontinue Zoloft and institute appropriate medical intervention in patients with symptomatic hyponatremia. Applying that instruction requires a measured sodium result and clinical assessment of the symptoms. Urgent assessment should begin immediately when the presentation warrants it, while laboratory testing and evaluation proceed.

For the prescriber, the first decision is how promptly the patient needs assessment, including serum sodium when indicated. A medication change should follow the clinical findings rather than an assumed psychiatric explanation.

The Association of Medicine and Psychiatry's expert consensus highlights the first two to four weeks after initiation or a significant dose increase as a period of suspicion. Added risk factors can also matter during longstanding treatment.

Establish the actual start date, dose changes and symptom onset. Ask what else changed, including other medicines, illness and fluid intake. The timeline helps direct the investigation; the work-up determines what it supports.

Low sodium alone does not establish the syndrome of inappropriate antidiuretic hormone secretion, or SIADH. AMP's differential includes primary polydipsia, in which excessive water intake usually produces very dilute urine. Serum and urine osmolality, urine sodium and volume assessment help distinguish causes. Age and thiazides can complicate the urine pattern.

This gives the fluid history a specific purpose in a psychiatric assessment. Naming an antidepressant as the cause before that work is done can obscure a different contributor and lead to an unnecessary treatment change.

Correction requires medical coordination: overly rapid correction can cause osmotic demyelination, a serious neurologic injury. The prescribing handoff should connect the suspected contributors, assessment findings and medication decision with the medical plan.

Jung and colleagues' 2026 study compared antidepressant classes in South Korean hospital records. Its SSRI comparator was all other antidepressant classes, rather than non-use. The main propensity model adjusted for age group, sex and the Charlson Comorbidity Index.

The SSRI association was statistically significant in the main analysis, the subgroup aged 60 and older, and the 30-, 60- and 90-day analyses. Two further analyses adding co-medications or restricting the population to people with follow-up blood testing retained estimates above 1 but confidence intervals included no difference. The authors recommend close sodium monitoring after SSRI initiation, especially early in treatment and in older adults.

The All of Us study authors caution against switching from duloxetine to sertraline on their findings without prospective randomized evidence. They also suggest that duloxetine users might benefit from closer monitoring, given risks from the medicine or the conditions for which it was prescribed.

Both papers support attention to sodium risk. Their monitoring recommendations are author interpretations of observational findings; neither study tested whether a monitoring strategy improves outcomes. That distinction permits a useful clinical response without treating a recommended strategy as a demonstrated benefit. Treatment choice still needs the patient's indication, prior response and medical findings.

AMP's consensus describes tiered actions: selected mild, asymptomatic cases may prompt dose reduction or tapering with repeat sodium assessment, while more serious presentations may require discontinuation and inpatient evaluation. These are expert recommendations, not a universal rule for every low result. For symptomatic patients, the Zoloft label directs discontinuation and appropriate medical intervention.

A laboratory result therefore needs interpretation in its clinical setting. The degree of sodium reduction, symptoms, time course and psychiatric consequences of changing treatment belong in the decision. A mildly abnormal result and a patient with severe new confusion require different responses.

AMP regards baseline sodium measurement in higher-risk patients as prudent expert opinion. Its algorithm lacks randomized validation, and the authors call for studies of baseline and serial monitoring's effects on morbidity and mortality.

A reasoned plan can acknowledge that evidence gap while specifying what will happen for this patient. State how promptly assessment will occur, who will review the result, and how findings will reach the prescriber. Urgent symptoms should not wait for a planned monitoring date.

At follow-up, return to the change that prompted concern: what happened to cognition, alertness or balance, what the assessment found, and what treatment decision followed. The medication review is more useful when it stays connected to the patient's condition rather than ending with a laboratory order.

Source note: Sources reviewed October 16, 2026. This is a practical synthesis of U.S. labeling, expert consensus and observational research, not a new monitoring guideline. Assessment and follow-up suggestions are editorial applications. No universal testing interval, preferred antidepressant, sodium-correction regimen or individualized treatment plan is established here.

Educational Disclaimer: The Psychiatric Record provides general educational information for psychiatric and mental-health professionals. Content does not constitute medical, legal, regulatory, compliance, billing, or other professional advice; does not establish a standard of care; and is not a substitute for independent professional judgment. Appropriate assessment and treatment depend on the individual, setting, and current authoritative guidance. Patients should coordinate treatment decisions with their treating clinicians.